Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Peter A. W. te Boekhorst"'
Autor:
Rinse Ubbink, Lucia W. J. M. Streng, Nicolaas J. H. Raat, Floor A. Harms, Peter A. W. te Boekhorst, Robert J. Stolker, Egbert G. Mik
Publikováno v:
Biomedicines, Vol 11, Iss 7, p 1873 (2023)
In light of the associated risks, the question has been raised whether the decision to give a blood transfusion should solely be based on the hemoglobin level. As mitochondria are the final destination of oxygen transport, mitochondrial parameters ar
Externí odkaz:
https://doaj.org/article/5a42e3e2173b4609b07f568528588d43
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e595 (2021)
Externí odkaz:
https://doaj.org/article/63b2ba10b3264ce284e909f6d531b134
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Current treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) is effective in many patients, but is not curative and frequently limited by intolerance or resistance. Also, treatment free remission is a novel option for CML
Externí odkaz:
https://doaj.org/article/59280be051e0463c9d2df3eea2f43316
Autor:
Alessandro M. Vannucchi, Peter A. W. te Boekhorst, Claire N. Harrison, Guangsheng He, Marianna Caramella, Dietger Niederwieser, Françoise Boyer-Perrard, Minghui Duan, Nathalie Francillard, Betty Molloy, Monika Wroclawska, Heinz Gisslinger
Publikováno v:
Haematologica, Vol 104, Iss 5 (2019)
EEXPAND (phase Ib, dose-finding study) evaluated the starting dose of ruxolitinib in patients with myelofibrosis with baseline platelet counts of 50-99×109/L. The study consisted of dose-escalation and safety-expansion phases. Based on the baseline
Externí odkaz:
https://doaj.org/article/dcdd30fc08a34d069d9bc9af3fd3e65b
Autor:
Madelon van Agteren, Willem Weimar, Annelies E. de Weerd, Peter A. W. te Boekhorst, Jan N. M. Ijzermans, Jaqueline van de Wetering, Michiel G. H. Betjes
Publikováno v:
Journal of Transplantation, Vol 2014 (2014)
This study describes the single center experience and long-term results of ABOi kidney transplantation using a pretransplantation protocol involving immunoadsorption combined with rituximab, intravenous immunoglobulins, and triple immune suppression.
Externí odkaz:
https://doaj.org/article/2a9358ad322442dd9ac78b7c53c93225
Autor:
Mar Bellido, Peter A. W. te Boekhorst
Publikováno v:
Advances in Hematology, Vol 2012 (2012)
JAK2 is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of JAK2 occurs in myeloproliferative neoplasms by different mechanisms. As a consequence, JAK2 inhibitors have been designed to s
Externí odkaz:
https://doaj.org/article/f3891921da364fcf90182c5640924357
Autor:
Stefan Sleijfer, John W.M. Martens, Harmen J.G. van de Werken, Corine M. Beaufort, Anieta M. Sieuwerts, Job van Riet, Nikolas H. Stoecklein, Jaco Kraan, Yorick Sandberg, Peter A. W. te Boekhorst, Martijn P. Lolkema, Wytske M. van Weerden, Anouk C. de Jong, Paul Hamberg, S. Erkens-Schulze, Lisanne F. van Dessel, L. Mout, Thomas L.C. Woo, Ronald de Wit, Rui P L Neves
Publikováno v:
European Journal of Cancer, 150, 179-189. Elsevier Ltd.
Background: Circulating tumour cell (CTC)–derived organoids have the potential to provide a powerful tool for personalised cancer therapy but are restrained by low CTC numbers provided by blood samples. Here, we used diagnostic leukapheresis (DLA)
Autor:
Sonja Zweegman, Nicolaas Schaap, Peter A. W. te Boekhorst, Sabina Kersting, Harry R. Koene, Stefanie Slot, Matthijs Westerman, Reinier Raymakers, Harry C. Schouten, Lambert F.R. Span
Publikováno v:
Clinical Lymphoma, Myeloma and Leukemia, 19(10), 624. Cancer Media Group
Clinical Lymphoma Myeloma & Leukemia, 19, 10, pp. 624-634
Clinical Lymphoma Myeloma & Leukemia, 19(10), 624-634. Cancer Media Group
Slot, S, Raymakers, R A P, Schaap, N, Span, L F R, Koene, H R, Kersting, S, te Boekhorst, P A W, Westerman, M, Schouten, H C & Zweegman, S 2019, ' Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature ', Clinical Lymphoma, Myeloma and Leukemia, vol. 19, no. 10, pp. 624-634 . https://doi.org/10.1016/j.clml.2019.07.005
Clinical Lymphoma, Myeloma and Leukemia, 19(10), 624-634. Cancer Media Group
Clinical Lymphoma Myeloma & Leukemia, 19, 624-634
Clinical Lymphoma Myeloma & Leukemia, 19, 10, pp. 624-634
Clinical Lymphoma Myeloma & Leukemia, 19(10), 624-634. Cancer Media Group
Slot, S, Raymakers, R A P, Schaap, N, Span, L F R, Koene, H R, Kersting, S, te Boekhorst, P A W, Westerman, M, Schouten, H C & Zweegman, S 2019, ' Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature ', Clinical Lymphoma, Myeloma and Leukemia, vol. 19, no. 10, pp. 624-634 . https://doi.org/10.1016/j.clml.2019.07.005
Clinical Lymphoma, Myeloma and Leukemia, 19(10), 624-634. Cancer Media Group
Clinical Lymphoma Myeloma & Leukemia, 19, 624-634
Real-life data on the treatment of myelofibrosis patients with baseline thrombocytopenia with ruxolitinib are limited. We present the outcomes of thrombocytopenic Dutch patients treated within a compassionate-use program. Additionally, we performed a
Publikováno v:
Transfusion and Apheresis Science, 60(5):103192. Elsevier Ltd.
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by clinical findings including thrombosis and/or obstetric complication and laboratory findings, e.g. ≥1 positive antiphospholipid antibodies (aPL) (lupus anticoagulant,
Autor:
Robyn M. Scherber, Claire N. Harrison, Ruben A. Mesa, Stefanie Slot, Junqing Xu, Jean-Jacques Kiladjian, Zefeng Xu, Pablo J. Muxi, Chiara Paoli, Harry C. Schouten, Lydia Roy, Peter A. W. te Boekhorst, Robert Peter Gale, Norman Maldonado, Thomas Lehmann, Karin Bonatz, Maria Luisa Ferrari, Federico Sackmann, Jean Christophe Ianotto, Peihong Zhang, Giovanni Barosi, Alessandro Rambaldi, Bjorn Andreasson, Peter L. Johansson, Xiujuan Sun, Allison H. Scotch, Ana Kerguelen Fuentes, Jean-Yves Cahn, Deepti Radia, Suzan Commandeur, Zhijian Xiao, Jan Samuelsson, Heidi E. Kosiorek, Francisco Cervantes, Yue Zhang, Gabriel Etienne, Heike L. Pahl, Françoise Boyer, Martin Griesshammer, Francesco Passamonti, Konstanze Döhner, Gunnar Birgegård, Sonja Zweegman, Carlos Besses, Alessandro M. Vannucchi, Dana Ranta, Frank Stegelmann, Dolores Hernández-Maraver, Amylou C. Dueck, Holly L. Geyer, Tiziano Barbui, Andreas Reiter
Publikováno v:
Leukemia Research, 63, 34-40. Elsevier Ltd.
Scotch, A H, Kosiorek, H, Scherber, R, Dueck, A C, Slot, S, Zweegman, S, Boekhorst, P A W T, Commandeur, S, Schouten, H, Sackmann, F, Fuentes, A K, Hernández-Maraver, D, Pahl, H L, Griesshammer, M, Stegelmann, F, Döhner, K, Lehmann, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J C, Ranta, D, Roy, L, Cahn, J Y, Harrison, C N, Radia, D, Muxi, P, Maldonado, N, Besses, C, Cervantes, F, Johansson, P L, Barbui, T, Barosi, G, Vannucchi, A M, Paoli, C, Passamonti, F, Andreasson, B, Ferrari, M L, Rambaldi, A, Samuelsson, J, Birgegard, G, Xiao, Z, Xu, Z, Zhang, Y, Sun, X, Xu, J, Kiladjian, J J, Zhang, P, Gale, R P, Mesa, R A & Geyer, H L 2017, ' Symptom burden profile in myelofibrosis patients with thrombocytopenia : Lessons and unmet needs ', Leukemia Research, vol. 63, pp. 34-40 . https://doi.org/10.1016/j.leukres.2017.10.002
Leukemia Research, 63, 34-40. Elsevier Limited
Leuk Res
Scotch, A H, Kosiorek, H, Scherber, R, Dueck, A C, Slot, S, Zweegman, S, Boekhorst, P A W T, Commandeur, S, Schouten, H, Sackmann, F, Fuentes, A K, Hernández-Maraver, D, Pahl, H L, Griesshammer, M, Stegelmann, F, Döhner, K, Lehmann, T, Bonatz, K, Reiter, A, Boyer, F, Etienne, G, Ianotto, J C, Ranta, D, Roy, L, Cahn, J Y, Harrison, C N, Radia, D, Muxi, P, Maldonado, N, Besses, C, Cervantes, F, Johansson, P L, Barbui, T, Barosi, G, Vannucchi, A M, Paoli, C, Passamonti, F, Andreasson, B, Ferrari, M L, Rambaldi, A, Samuelsson, J, Birgegard, G, Xiao, Z, Xu, Z, Zhang, Y, Sun, X, Xu, J, Kiladjian, J J, Zhang, P, Gale, R P, Mesa, R A & Geyer, H L 2017, ' Symptom burden profile in myelofibrosis patients with thrombocytopenia : Lessons and unmet needs ', Leukemia Research, vol. 63, pp. 34-40 . https://doi.org/10.1016/j.leukres.2017.10.002
Leukemia Research, 63, 34-40. Elsevier Limited
Leuk Res
Myelofibrosis is a myeloproliferative neoplasm associated with progressive cytopenias and high symptom burden. MF patients with thrombocytopenia have poor prognosis but the presence of thrombocytopenia frequently precludes the use of JAK2 inhibitors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022b1a49d48b9e484baa96dcb56756c9
http://hdl.handle.net/11383/2066806
http://hdl.handle.net/11383/2066806